Unicycive says FDA issues CRL for OLC NDA over third-party manufacturing deficiencies

Unicycive Therapeutics

Unicycive Therapeutics

UNCY

0.00
  • Unicycive received an FDA complete response letter for its resubmitted NDA for oxylanthanum carbonate for hyperphosphatemia in dialysis patients.
  • The FDA cited unresolved deficiencies at a third-party manufacturing vendor, repeating issues flagged in a June 2025 complete response letter.
  • The agency did not inspect the vendor during the resubmission review, leaving manufacturing compliance as the central approval barrier.
  • The FDA raised no new concerns on efficacy or safety, requesting no additional clinical data.
  • Labeling discussions continue; the latest FDA communication was on June 29 regarding carton and container labels.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606300705PRIMZONEFULLFEED9754575) on June 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.